Translational Research Cancer Centers Consortium

Translational Research Cancer Centers Consortium

Expediting Progress in Cancer Immunotherapy

Wednesday, February 15, 2017




2017 Sponsors

Thursday, February 16, 2017

2 - 6 pm Registration & Poster Setup (Exhibit Hall)
2:45 pm Welcome Address (Exhibit Hall)
3 pm

Introduction of Keynote Speaker
Sponsored by Immudex

3 - 4 pm

Keynote Address: “Melanoma Neoantigen Discovery”
Gerald P. Linette, MD, PhD
Chief Medical Officer for Cancer Immunotherapy
Clinical Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania

4 - 4:15 pm Break
4:15 - 6 pm

Symposium 1 – Strategies to ignite productive T cell immunity in cancer

Fumito Ito, Assistant Professor, Rosswell Park Cancer Institute
Reprogramming tumor-specific T cells with pluripotency for cancer therapy

Patrick Forde, Assistant Professor, Johns Hopkins University
Moving checkpoint therapy to the neoadjuvant setting in lung cancer

Two short talks from Abstract Submissions

6 - 9 pm Welcome Reception (Exhibit Hall)

Daniel Powell, Ph.D.
Associate Professor of Pathology and Laboratory Medicine
Ovarian Cancer Research Center
Abramson Cancer Center
Perelman School of Medicine
University of Pennsylvania


8 am Registration
8:30 - 9:45 pm

Concurrent Trainee Sessions 1 and 2

Session 1 - Tumor Microenvironment (Snowflake Room)

Session 2 - Cell Therapies (Sunburst Room)

9:45 - 10 am Browse Trainee Posters and Sponsor Exhibits (Exhibit Hall)
10 am - 12:30 pm

Symposium 2 – New translational models for cancer immunotherapy

Avery Posey, Instructor, University of Pennsylvania
Defining the potential of immunotherapy using canine models

Heather Gibson, Research Scientist, Karmanos Cancer Institute
Diversity and genetic linkage analysis of cancer vaccine response in outbred cats and mice?

Miguel Tam, PhD - Senior Product Manager
Fighting cancer from multiple angles: Exploring RANK-RANKL, PD-L1 and cell depletion in the control of melanoma in mouse models

William Merritt, Program Director, National Cancer Institute
NIH Funding and New Initiatives

Kathleen Sturgeon, Assistant Professor, Penn State University
Exercise – a key determinant of outcomes with cancer therapy

Platinum Sponsor Presentation

12:30 - 1:30 pm Advocate Networking Lunch (Grand Ballroom)
1:30 - 2:45 pm

Concurrent Trainee Sessions 3 and 4

Session 3 - Translational and Clinical Cancer Studies (Snowflake Room)

Session 4 – Regulators of Immune Resistance/Response (Sunburst Room)

2:45 - 3 pm Break
3 - 5:30 pm

Symposium 3 – The tumor microenvironment and innate immunity – key components to the success of cancer immunotherapy

Frank Housseau, Assistant Professor, Johns Hopkins University
"IL-17 – a key regulator of carcinogenesis"

Joseph Skitzki, Associate Professor, Roswell Park Cancer Institute
"Visualizing the tumor microenvironment using real-time clinical imaging"

Zobeida Cruz-Monserrate, Assistant Professor, OSU Cancer Center
"IL-6 as a regulator of PD-L1 checkpoint therapy "

Emidio Pistilli, Assistant Professor, West Virginia University
"Multifaceted roles for IL-15 in cancer"

Platinum Sponsor Presentation

5:30 - 6:15 pm Networking Session
6:15 - 8:30 pm Dinner stations and formal poster presentations (Exhibit Hall)

2017 Annual Meeting Agenda

Friday, February 17, 2017


Click here for sponsorship Information.

Contact: Stephen T. Haley, Ph.D - or (301) 606-9145 if you are interested in sponsoring the TRCCC Annual Meeting .

8:15 - 9:45 am

Concurrent Trainee Sessions 5 and 6

Session 5 - Viral therapies/ Vaccines (Snowflake Room)

Session 6 - Emerging Therapies (Sunburst Room)

9:45 - 10:15 am Break and hotel room check out
10:15 - 11 am

Immunotherapy Rounds: Translating between Lab and Clinic (Exhibit Hall)

11 am - 12:30 pm

Symposium 4 – Defining mechanisms of immune resistance and response to cancer therapy

Julien Fourcade, Assistant Professor, U of Pittsburgh
"Unraveling immune checkpoints that regulate tumor-specific T cell immunity in cancer"

Egne Petrosiute, Assistant Professor, Case Western Reserve University
"A novel role of Cdk5 as a tumor immune response regulator"

Andy Minn, Assistant Professor, U of Pennsylvania
"Determinants of response/resistance to cancer immunotherapy"

12:30 - 1:30 pm Lunch
1:40 pm Introduction of Keynote Speaker (Exhibit Hall)
1:45-2:40 pm

Closing Keynote Address: “Immune checkpoint inhibitors – the beginning of a revolution in cancer therapy ”
Julie Brahmer, M.D.
Interim director, Sidney Kimmel Comprehensive Cancer Center (Bayview)
Director of Thoracic Oncology
Johns Hopkins University

2:40 pm Trainee Award Ceremony (Exhibit Hall)
3:15 pm Closing Remarks and Meeting Adjournment


Copyright Translational Research Cancer Centers Consortium

Carl June, M.D.
Richard W. Vague Professor in Immunotherapy
Department: Pathology and Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania 

2017 Annual Meeting Chairs

Gregory Beatty, M.D., Ph.D.
Assistant Professor of Medicine,
Perelman School of Medicine
Attending Physician, 
University of Pennsylvania Health System